Main Article Content

Chiara Agrati
Veronica Bordoni
alessandra sacchi
germana grassi
nicola petrosillo
emanuele nicastri
franca del nonno
giampiero d'offizi
fabrizio palmieri
luisa marchioni
maria rosaria capobianchi
andrea antinori
giuseppe ippolito
Michele Bibas


P-selectin, Covid-19, Endothelium, Platelets



Coronavirus disease 2019 (COVID-19) is mainly a respiratory tract disease and acute respiratory failure with diffuse microvascular pulmonary thrombosis are critical aspects of the morbidity and mortality of this new syndrome.


The aim of our study was to investigate, in severe COVID-19 hospitalized patients, the  P-selectin plasma concentration as a biomarker of endothelial dysfunction and platelet activation.


46 patients with severe or critical SARS-CoV-2 infection were included in the study. Age-matched patients then were divided in those requiring admission to the intensive care unit (ICU, ICU cases) vs those not requiring ICU hospitalization (non-ICU cases). Blood samples of severe COVID-19 patients were collected at the time of hospital admission. The quantification of soluble P-selectin was performed by ELISA assay.


Our study showed a higher P-selectin plasma concentration in patients with Covid-19, regardless of ICU admission, compared to the normal reference values and compared to ten contextually sampled healthy donors (HD); (COVID-19): median 65.2 (IQRs: 45.1-81.1) vs. HD: 40.3 (IQRs: 24.3-48.7), p=0.0023). Moreover, results showed a significant reduction of P-selectin after platelets removal in HD, in contrast, both ICU and non-ICU COVID-19 patients showed similar high levels of P-selectin with and without platelets.


Elevation of P-selectin suggests a central role of platelet endothelium interaction as part of the multifaced pathogenic mechanism of COVID-19 leading to the local activation of hemostatic system forming pulmonary thrombi. Further work is necessary to determine the therapeutic role of antiplatelets agents or of the anti P-selectin antibody Crizanlizumab.


Download data is not yet available.

Abstract 1134
PDF Downloads 434
HTML Downloads 162


References :

1. Guan WJ, Ni ZY, Hu Y, Liang WH, et al .:Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi:10.1056/NEJMoa2002032.

2. Hamming I, Timens W, Bulthuis ML, Lely AT et al.: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631-7.

3. Varga Z, Flammer AJ, Steiger P et al.: Endothelial cell infection and endotheliitis in
COVID-19. Lancet. 2020 May 2; 395(10234):1417-1418. doi: 10.1016/S0140-6736(20) 30937-5. Epub 2020 Apr 21.

4. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of
therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019 Feb 28;133(9):906-918. doi: 10.1182/blood-2018-11-882993

5. Ivanov II, Apta BHR, Bonna AM, Harper MT. Platelet P-selectin triggers rapid surface exposure of tissue factor in monocytes. Sci Rep. 2019 Sep 16;9(1):13397. doi:

6. Tan Li, Wang Qi, Zhang D. et al.: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4.

7. Zuo Y, Yalavarthi S, Shi H et al.: Neutrophil extracellular traps in COVID-19. JCI Insight. 2020 Apr 24. pii: 138999. doi: 10.1172/jci.insight.138999. [Epub ahead of print]

8. Du F, Jiang P, He S, Song D, Xu F. Antiplatelet Therapy for Critically Ill Patients: A
Pairwise and Bayesian Network Meta-Analysis. Shock. 2018 Jun;49(6):616-624.

9. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and
transfusion-related acute lung injury. Blood. 2019 Apr 25;133(17):1840-1853

10. Blair HA. Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.